Quantify indirect costs of treatment in respiratory and allergic diseases

The aim of this study is to mModel the cost implications of 1-2 of the most common comorbidities identified by Sweeney et al (e.g. diabetes) and to develop disease models (via the REG Cost Effectiveness Working Group) with a view to then licensing out the use of these models for a usage

Lead Investigator:
Jon Campbell
Research Team:
Status: Planned Study, Seeking Funding
Support: 
Registration: 
Documents and Publications:
Protocol
Abstracts
Presentations
Final Publications
Additional Material